Kancera AB (publ)

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. Show More...

  • Website https://www.kancera.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.01 SEK
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share SEK -0.57 -0.83 -1.24 -0.17 -0.14 -0.16 -0.17 -0.37 -0.24 -0.17 -0.17
    Dividends SEK
    Payout Ratio % *
    Shares Mil 22.0 25.0 31.0 43.0 110.0 123.0 137.0 153.0 185.0 212.0 212.0
    Book Value Per Share * SEK 1.2 0.36 0.18 0.25 0.21 0.42 0.27 0.22 0.11 0.08
    Free Cash Flow Per Share * SEK -0.94 -0.96 -0.3 -0.09 -0.19 -0.14 -0.25 -0.28 -0.21
    Return on Assets % -51.0 -68.5 -114.66 -33.48 -51.49 -61.45 -44.42 -90.45 -94.95 -80.31 -80.31
    Financial Leverage (Average) 1.27 1.53 3.4 1.35 1.33 1.25 1.23 1.32 1.36 2.55 2.55
    Return on Equity % -64.57 -99.59 -213.29 -60.67 -69.11 -79.7 -54.78 -114.41 -127.48 -142.17 -142.17
    Return on Invested Capital % -64.57 -70.55 -146.01 -66.07 -65.66 -75.43 -52.09 -108.2 -121.36 -129.34 -129.34
    Interest Coverage -278.07 -493.53 -167.67 -167.67
    Current Ratio 2.72 3.36 1.25 2.96 3.48 4.58 6.11 3.41 2.38 0.6 0.6
    Quick Ratio 2.72 3.36 0.91 2.74 3.02 3.92 5.43 2.93 2.12 0.54 0.54
    Debt/Equity 0.26 1.01 0.08 0.06 0.07 0.05 0.08 0.02 0.03 0.03